A network view of disease and compound screening.pdfVIP

P e r s P e c t i v e s All stakeholders must be willing to work 3. Iakoubova, O. A. et al. Polymorphism in KIF6 or causal chain, leading to disease, and then gene and benefit from statins after acute coronary together to help reshape these incentive syndromes. J. Am. Coll. Card. 51, 449–455 to interfere at one of these steps — by structures. Only with this type of coopera- 2008 . inhibiting a crucial enzyme or blocking an 4. Zafar, I., Levy, T. Damergy, S. Third Wave tion will all stakeholders reap the benefits Technologies Report, Hospital Supplies and Medical important receptor, for example. The drug that personalized medicine has to offer. Devices. Deutsche Bank, 12 May, 2008 . target is often chosen based on the pheno- 5. Davies, L. Welch, H. G. Increasing incidence of Jerel C. Davis, Laura Furstenthal, Amar A. Desai, thyroid cancer in the United States, 1973–2002. type of a mouse that has been genetically Saumya Sutaria, Edd Fleming and Philip Ma JAMA 295, 2164–2167 2006 . engineered to express hypermorphic or, more 6. Goodman, C. et al. The Value of Diagnostics, are at McKinsey, 3075A Hansen Way, Palo Alto, Innovation, Adoption and Diffusion into Health Care. commonly, hypomorphic alleles. An assay California 94304, USA. The Southern California Biomedical Council [online], for the target is then designed as described Troy Norris is at McKinsey, 55 East 52nd Street, /pdfs/thevalueofdiagnostics.pdf above , HTS is performed and lead com- 2005 . New York, New York 10022, USA. pounds are identified. Unfortunately, most of Correspondence to P.M. the drug candidates that eventually emerge e?mail: Philip_Ma@ DATABASES entrez Gene: from this process and enter clinical studies doi:10.1038/nrd2825 Published online 20 March 2009 /entrez/query.fcgi?db gene ultimately fail, often because of either poor BRCA1 | KIF6 1 efficacy or unanticipated side effects . 1. Iakoubova, O. A. et al. Association of the Trp719Arg FURTHER INFORMATION There are two